1. Home
  2. MXL vs SRPT Comparison

MXL vs SRPT Comparison

Compare MXL & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxLinear Inc.

MXL

MaxLinear Inc.

HOLD

Current Price

$93.87

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$17.64

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXL
SRPT
Founded
2003
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.5B
IPO Year
2009
2000

Fundamental Metrics

Financial Performance
Metric
MXL
SRPT
Price
$93.87
$17.64
Analyst Decision
Strong Buy
Hold
Analyst Count
6
29
Target Price
$41.67
$25.85
AVG Volume (30 Days)
4.9M
2.6M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
46.08
N/A
EPS
N/A
2.88
Revenue
$478,596,000.00
$2,198,237,000.00
Revenue This Year
$22.10
N/A
Revenue Next Year
$10.70
N/A
P/E Ratio
N/A
$5.99
Revenue Growth
N/A
15.58
52 Week Low
$11.26
$10.42
52 Week High
$106.28
$43.92

Technical Indicators

Market Signals
Indicator
MXL
SRPT
Relative Strength Index (RSI) 64.07 42.49
Support Level $15.36 $17.11
Resistance Level $104.27 $18.10
Average True Range (ATR) 11.84 0.77
MACD -2.00 -0.09
Stochastic Oscillator 52.17 28.85

Price Performance

Historical Comparison
MXL
SRPT

About MXL MaxLinear Inc.

MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: